Does DEGARELIX Cause Malignant neoplasm progression? 44 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 44 reports of Malignant neoplasm progression have been filed in association with DEGARELIX (FIRMAGON). This represents 1.2% of all adverse event reports for DEGARELIX.
44
Reports of Malignant neoplasm progression with DEGARELIX
1.2%
of all DEGARELIX reports
8
Deaths
13
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DEGARELIX?
Of the 44 reports, 8 (18.2%) resulted in death, 13 (29.5%) required hospitalization, and 3 (6.8%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DEGARELIX. However, 44 reports have been filed with the FAERS database.
What Other Side Effects Does DEGARELIX Cause?
Injection site pain (296)
Injection site erythema (246)
Hot flush (199)
Fatigue (195)
Injection site swelling (183)
Product storage error (177)
Pyrexia (170)
Off label use (128)
Asthenia (123)
Death (120)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DEGARELIX Alternatives Have Lower Malignant neoplasm progression Risk?
DEGARELIX vs DELAFLOXACIN MEGLUMINE
DEGARELIX vs DELAMANID
DEGARELIX vs DELANDISTROGENE MOXEPARVOVEC-ROKL
DEGARELIX vs DELAVIRDINE
DEGARELIX vs DELORAZEPAM